<DOC>
	<DOCNO>NCT01356927</DOCNO>
	<brief_summary>Contraception abortion important public health issue , woman abortion high risk additional unintended pregnancy . In context first trimester medical abortion , standard care administer long-acting reversible contraception , include etonogestrel implant ( Implanon ) depot medroxyprogesterone acetate ( DMPA ) , follow-up appointment abortion . The investigator plan conduct prospective observational pilot study evaluate satisfaction subject select either contraceptive implant DMPA give first day medical abortion , oppose follow-up appointment . The investigator also assess continuation DMPA Implanon 3 , 6 , 9 , 12 month initial date administration . In addition , investigator assess total day bleed abortion , follow-up rate evaluation completion medical abortion , efficacy medical abortion . A total 40 participant recruit , 20 choose Implanon 20 choose DMPA . They ask fill questionnaire course study , follow one year . The study duration include data analysis two year .</brief_summary>
	<brief_title>Same-day Long-acting Reversible Contraception Medication Abortion</brief_title>
	<detailed_description>This prospective , observational pilot study administration either Implanon DMPA first day medication abortion . Subjects two cohort follow one year , questionnaire administer intake , 2 week , 4 week , 3 , 6 , 9 , 12 month recruitment . On day recruitment , patient consent medication abortion contraceptive method ( Implanon DMPA ) , provider ask patient interested participation study . If patient interested , research assistant investigator call discus study private potential subject . Consent obtain investigator , intake questionnaire baseline contraceptive demographic data administer . Mifepristone medication abortion administer per protocol provider , Implanon DMPA administer . The clinician provide medication abortion person investigator consent research . A bleeding diary card give subject record daily bleed . The subject request return card mail 4 week , give address stamped envelope . Subjects schedule 7-day follow-up appointment per medication abortion protocol , visit , short questionnaire regard satisfaction time contraceptive method , number day bleed administer . Subjects contact preferred modality ( phone , email , text message ) 2 week , assess total day bleed . If subject continue bleeding , contact 4 week assess total day bleed . At contact point , satisfaction timing placement , satisfaction contraceptive method assess via Likert scale . Additional contact make 3 , 6 , 9 , 12 month subject assess continuation contraceptive method . If unable contact subject list emergency contact total five time preferred alternate modality contact , letter send along self-addressed stamp envelope . Outcomes ( Indicate anticipate primary secondary outcome measure ) : The primary study objective assess follow : 1 . Subject satisfaction timing placement determine questionnaire 2 . Continuation contraceptive method 3 , 6 , 9 , 12 month determine questionnaire The secondary study objective assess follow : 1 . Total day bleed abortion 2 . Follow-up rate evaluation completion medication abortion 3 . Failure rate medication abortion 4 . The number woman screen participation 5 . Reasons refusal participate study 6 . Reasons ineligibility 7 . The number woman change contraceptive method year follow-up .</detailed_description>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Desiring eligible medication abortion Desiring eligible etonogestrel implant DMPA Contraindications DMPA etonogestrel implant per CDC guideline regard United States Medical Eligibility Contraceptive Use ( Centers Disease Control , 2010 ) Contraindications mifepristone misoprostol include ectopic pregnancy , pregnancy intrauterine device place , chronic adrenal failure , significant anemia , bleed disorder , chronic steroid use , inability follow , lack emergency medical access , allergy mifepristone misoprostol , malignant liver tumor , benign hepatocellular adenoma , systemic lupus erythematosis antiphospholipid antibody syndrome , active liver disease , history breast cancer current breast cancer Nonworking telephone number ( assessed initial visit ) Unable give inform consent , unable speak English , Spanish , French Creole Unable contact confidentiality issue Currently breastfeed Intending move away Boston area within one year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>long act reversible contraception</keyword>
	<keyword>medical abortion</keyword>
	<keyword>DMPA</keyword>
	<keyword>etonogestrel implant</keyword>
	<keyword>Implanon</keyword>
	<keyword>contraceptive continuation</keyword>
</DOC>